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Abstract
Viral infections of the central nervous system (CNS) in infants are rare; however,
they are associated with high morbidity and mortality rates. These virus infections often
induce strong innate immune responses in the brain including: the production of
cytokines and chemokines, the activation of astrocytes and microglia and the recruitment
of macrophages. Innate immune responses are often initiated by toll-like receptors
(TLR). Several studies have demonstrated that toll-like receptor 7 (TLR7) can be
stimulated by single-stranded RNA from multiple viruses. In the current study, we
examined the mechanism by which TLR7 contributes to neuroinflammation in the
neonatal brain using a mouse model of polytropic retrovirus infection. We found that
TLR7 deficiency had no effect on neurologic disease, viral replication, or induction of
interferon beta mRNA. However, TLR7 deficiency significantly altered
neuroinflammatory responses including proinflammatory cytokine production, astrocyte
activation, and microglial/macrophage activation. To our knowledge, this is the first
demonstration of the necessity of TLR7 for innate immune responses to retrovirus
infection in vivo. Additionally, this indicates that the immune response to retrovirus in the
CNS may not be essential for disease pathogenesis in neonates.
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Chapter 1: Introduction
Fr98 infection of neonates induces the innate immune response (1, 2). Activation
of microglial cells and astrocytes is observed as well as the production of
proinflammatory cytokines and chemokines as detected by both mRNA and protein
expression (3-12). Induction of the innate immune response may play a role in either
suppression of viral replication or detrimental pathology induced by the viral infection
(13-16). Since innate immune responses are often initiated by stimulation of toll-like
receptors (17), their study is warranted to discover opportunities to intervene and treat
neuropathogenic viral infections in newborns. Toll-like receptor 7 (TLR7), which is
activated by single-stranded RNA from numerous viral families (18-22), is expressed on
brain capillary endothelial and microglial cells in neonates (23). The role of TLR7 in
retroviral infection and the induction of the innate immune response in the neonatal brain
are unknown. We hypothesize that TLR7 stimulation by virus infection initiates
neuroinflammatory pathways in the developing brain.
To determine the role of TLR7 in the virus-mediated host neuroinflammatory
response, we characterized the neuroinflammatory response to Fr98 retrovirus infection
in wildtype, heterozygous, and TLR7-deficient mice prior to clinical disease as well as in
animals exhibiting clinical signs of disease. Quantitative reverse transcriptase real time
polymerase chain reaction technology and multiplex analysis of cytokine and chemokine
proteins were utilized to calculate differences in gene expression levels between Fr98infected and mock-infected wild type and TLR7-deficient animals to determine which
neuroinflammatory pathways are dependent on TLR7 stimulation.
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Additionally, since the role of TLR7 in retroviral neuropathogenesis is unknown,
we infected wildtype, heterozygous, and TLR7-deficient mice with Fr98 retrovirus and
followed them for clinical signs of disease. Mice were scored as having neurologic
disease when signs of severe ataxia and/or seizures were apparent. Survival curve
analysis of disease onset was calculated to determine if TLR7 deficiency altered Fr98induced neuropathogenesis.

2

Chapter 2: Review of Literature
2.1: Innate Immune Response in the Brain
The brain is considered an immunologically privileged site due to the lack of
lymphatics and the presence of the blood brain barrier (BBB) that restricts immune cell
entry into the central nervous system (CNS). However, the immune privilege of the CNS
is incomplete. Inflammation can still occur in the CNS, by either a response to exogenous
antigens or self-antigens (autoimmunity) (24). Additionally, the innate immune response
in the brain may differ between adult and neonatal animals. While adult and neonatal
animals both possess tight junctions present at the blood-brain and blood-cerebrospinal
fluid (CSF) barriers, neonates also have additional types of junctions (plate, strap, wafer)
at the CSF-brain barriers that are not present in adults. The developing brain is also more
permeable to small insoluble lipid molecules and has specific transfer mechanisms for
certain proteins into CSF (25).
The innate immune system in the brain is composed of phagocytic cells
(monocytes/macrophages and polymorphonuclear phagocytes), natural killer cells,
interferons, and soluble factors (24). In addition, parenchymal macrophages, microglial
cells, and astrocytes also play a role in innate immunity. Key players in the innate
immune response in the CNS are microglia/macrophages. The CNS endogenous
microglia share many properties with macrophages since they develop from the same
hematopoietic line (26-28). When activated, both systemic macrophages and microglial
cells are able to phagocytize pathogens, cells, and cellular debris (28-31). There are two
types of microglial cells in the CNS, parenchymal microglia and perivascular microglia.
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The parenchymal microglial cells are not routinely repopulated by “fresh” monocytes, but
perivascular microglial cells are (32). When parenchymal microglial cells are not
activated, they play a role in signaling and support to neurons and astrocytes.
Astrocytes, which were once considered just “scaffolding” to support neurons,
have recently been shown to actively engage in critical events in the brain such as
regulation of the BBB permeability and entry of inflammatory cells (33), antigen
presentation (34, 35), and uptake of neurotransmitters (36). Astrocytes possess endfoot
processes which are in close physical proximity to the endothelial cells of the blood brain
barrier. This location places astrocytes in an ideal position to modulate the
transendothelial migration of blood cells into the brain parenchyma (37).
Experimentation with angiotensin-deficient mice demonstrated that restoration of the
blood brain barrier after injury was strictly dependent upon intact astrocyte function. It
has also been shown that monocyte-chemoattractant protein-1 produced by astrocytes
direct the migration of monocytes and lymphocytes across the endothelium of an in vitro
blood brain barrier model (38). Additionally, astrocytes respond to brain injury via
reactive gliosis, which is a proliferation of astrocytes in the damaged CNS. Brain lesions
of varying etiologies such as infection (i.e. HIV), autoimmunity (MS), degenerative
disorders (AD), ischemic or tumor damage are infiltrated by hypertrophic astrocytes
expressing elevated levels of glial fibrillary acidic protein (GFAP) (39). Reactive
astrocytes also display an increased expression of adhesion molecules compared to
resting astrocytes, as well as an increase in the production of cytokines, chemokines,
growth factors, and neuropeptides, confirming the involvement of these cells in immune
responses (40).
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2.2: Toll-like Receptors (TLRs)
The ability of the immune system to detect and recognize pathogens is critical for
mounting the appropriate immune response to adequately combat invading organisms.
In mammals, host defense against pathogens is dependent on two types of immunity,
innate immunity and acquired immunity (41). Pathogen detection by the innate immune
system occurs via pattern recognition receptors (PRRs), a class of immune-sensor
molecules that recognize microbes or microbial components. This recognition results in
the initiation of anti-pathogen gene expression that promotes the adaptive immune
response (42). Toll-like receptors are a class of PRRs that detect an array of pathogens
(43). The TLR family currently consists of 11 members (TLR1-TLR11) identified in
humans, and 12 TLRs identified in mice. TLRs are expressed primarily on cells which
are likely to be the first to encounter antigens (44-50), with dendritic cells, macrophages,
and neutrophils expressing the highest amount of receptors (51, 52). However, it appears
that the majority of the cells in the body express at least a subset of TLRs (53).
All of the TLRs are structurally similar (50). They are all type 1 transmembrane
proteins with a single domain that spans the membrane. While the majority of TLRs are
expressed on the surface of the cell, some are retained intracellularly, which allows for
optimal positioning to interact with certain pathogens invading the host (Fig. 1). For
example, TLRs 3, 7, 8 and 9 tend to localize on endocytic compartments (53). The
cytoplasmic region of the TLRs consists of a conserved domain (Toll/IL-1R) which
contains the cytosolic adaptor protein, myeloid differentiation factor 88 (MyD88), and is
responsible for intracellular signaling initiation. Signaling pathways can be MyD88dependent or MyD88-independent, with TLR3 and TLR4 signaling being the latter (54,
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55). MyD88 activation results in NF-кB and mitogen activated protein kinase (MAPK)
activation which results in the secretion of cytokines (55).

Figure 1. Toll-like receptors and their ligands, cellular locations, and secondary signaling
pathways (53).
The outer domains of TLRs are composed of varying length leucine-rich repeats,
which allows each TLR to recognize specific components of different pathogens,
providing ligand-specific activation. The pathogen-specific motifs on invading
organisms that allow for specific TLR recognition are known as pathogen-associated
molecular patterns (PAMPs) (53). Examples of PAMPs recognized by TLRs include:
lipopolyscaahride (TRL4) (56-58), flagellin (TRL5) (59), peptidoglycan and lipoproteins
(TRL2) (60-63), and deoxycytidylate phosphate deoxyguanylate (CpG) DNA (TLR9)
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(64, 65) (Fig. 1). Additionally, some TLRs work together in concert which results in even
greater ligand recognition specificity.
Pathogen activation of TLRs results in complex changes in the cellular
microenvironment that leads to the activation of the immune system. With regard to viral
infections, the purpose of TLR activation and immune system stimulation is to effectively
limit the replication and spread of the viral infection. When a TLR is engaged, TLR
signaling occurs which leads to induction of NF-kB, causing the transcription of
chemokines, proinflammatory cytokines, and the up-regulation of cell surface molecules
that are involved in the initiation of the adaptive immune response (66). Experiments in
mice and cultured human cells have shown that TLRs also influence adaptive immunity
by activating dendritic cells (DCs), which present antigen to T cells and release factors
that stimulate T cell differentiation and expansion (67). In addition to the stimulation of
humoral immunity by DCs, it has been shown in mice that direct activation of TLRs on B
cells is necessary for robust production of some classes of antigen-specific antibodies
(68). Therefore, TLRs play an influential role in the activation and stimulation of both
the innate and adaptive immune responses.
Recognition of viruses by TLRs also results in stimulation of the antiviral effector
type I interferon (IFN) cytokine system consisting of IFNα, IFNβ, IFNω, and IFNτ (69).
The production of type I IFNs plays a critical role in antiviral activity because the
cytokines both establish an anti-viral microenviroment and bridge the innate and adaptive
immune responses (70). Human DCs have been shown to be activated via TLRs to make
IFNα in response to multiple enveloped viruses, including influenza virus and HIV.
IFNα stimulates multiple protective pathways, such as enhancing the cytotoxic effect of
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natural killer cells and macrophages as well as stimulation T cell production or
maintaining activated T cells (71-74). IFNα has also been shown to induce Th1 activity in
human CD4+ T cells (75). Additionally, IFNα also stimulates intracellular RNAse
activity, which inhibits viral replication and can lead to viral clearance.
2.3: TLRs and Viral Infection
There are currently four classes of viral PAMPs that are recognized by TLRs
which include: double stranded RNA (dsRNA), single stranded RNA (ssRNA), CpG
DNA, and envelope glycoproteins (53). It is currently thought that viral ligands come
into contact with TLRs in antigen presenting cells (APC) through receptor-mediated
uptake of virus or viral fusion with endosomal membranes (76) (Fig. 2). For viruses that
either do not infect or cannot replicate in APCs, CD8+ T cells can be activated by crosspriming from DCs that engulf and then present antigen from apoptotic cells infected with
virus (67). An example of such an activation system is TLR3. TLR3 recognizes dsRNA
and its synthetic analogue, polyinosine-polycytidylic acid (polyI:C) (77). Since dsRNA
is a replication intermediate of RNA viruses, it is thought that TLR3 is activated when
virus-infected cells are lysed, releasing the dsRNA into the microcellular environment.
TLR9 is activated by CpG DNA (64, 65), which is thought to be exposed when virus
particles are taken into cells and degraded by endosomal acidification (Fig. 2). TLR9
activation and resultant IFN response occurs only in a MyD88-dependent fashion (7880). The viral PAMP for TLR7 and TLR8 is ssRNA, which requires endosomal
acidification and MyD88-dependent IFN production like TLR9 (18, 19). Because of these
similarities between TLR7, TLR8, and TLR9, they are thought to have evolved from a
common precursor and operate as a subfamily (49, 81). Viral envelope glycoproteins can
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act as PAMPs to activate TLR2, TLR3, and TLR4. These are unique in that the virus can
be detected at the earliest stage of infection, before viral gene expression or replication
occurs (53).

Figure 2. Viral stimulation and signaling pathways of endosomal toll-like receptors (76).

The identification of ssRNA as a ligand for TLR7 is a recent finding. During early
TLR research, the only known ligands of TLR7 and TLR8 were the family of
imidazoquinolines. Imidazoquinolines are low-molecular weight compounds that display
anti-viral and anti-tumor activity and are potent activators of immune cells (82-87). One
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imidazoquinoline family member, imiquimod, is currently used as an approved anti-viral
treatment in humans with human papillomavirus infections (88). From imiquimod a more
potent compound was derived, resiquimod (R-848). Through the use of MyD88-and
TLR7-deficient mice, both imidazoquinoline compounds have been shown to stimulate
immune cells via TLR7. Imidazoquinoline signaling, cytokine production by
macrophages, proliferation of splenocytes, and maturation of dendritic cells were all
absent in the MyD88-and TLR7-deficient mice stimulated with imidazoquinolines (89).
Additionally, guanosine analogues have also been shown to activate TLR7 and TLR8
(89-92). This discovery resulted in the investigation of ssRNA as a physiologic ligand,
since the structure of the guanosine analogues is similar to that of nucleic acids (19).
However, TLR7-deficient mice do not respond to imiquimod, R-848, or viral ssRNA,
which suggests that murine TLR8 was inactive (19, 89). Recent studies have
demonstrated that murine TLR8, along with human TLR8, can be stimulated by the coadministration of TLR7/8 ligands and poly-T oligodeoxynucleotides (pT-ODNs).
Administration of the pT-ODN stimulates TLR8, but inhibits TLR7-mediated responses
(93-95). To date, genomic RNA from influenza A virus, vesicular stomatitis virus, and
synthetic RNA oligonucleotide from human immunodefiency virus type-1 (HIV) have all
been found to activate TLR7 (18, 19, 21).
2.4: Role of TLR7 in HIV Immune Response
The main target cell of the HIV retrovirus is the CD4+ T cell, which does not
express TLR7 or TLR8 (22). However, TLR7 and TLR8 are expressed on multiple cell
types of the innate immune system, such as dendritic cells, macrophages, and monocytes
that are also targets of HIV (66). Selective cellular expression of TLR7 and TLR8 also
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occurs. For example, both TLR7 and TLR8 are expressed on B cells and monocytes,
TLR7 is expressed on both myeloid (mDC) and plasmacytoid dendritic cells (pDC), and
TLR8 is expressed on myeloid dendritic cells only (96-98). Stimulation of TLR7/8 on
these innate immune system cells by synthetic ssRNA from HIV retrovirus results in antiHIV activity, as demonstrated by NF-кB activation which results in the secretion of
proinflammatory and antiviral cytokines (18, 19, 66). It has also been shown that human
pDCs are activated and mature following exposure to intact HIV in vitro (99). Another
recent discovery is that activation of TLR7/8 results in opposing immune responses in
acute versus latent infection. Activation of TLR7/8 has been shown to block HIV
replication in vitro in acutely infected human aggregate lymphocyte cultures (HLAC) and
peripheral blood mononuclear cells (PBMC). Once TLR7/8 is activated, there is a
reduction of HIV co-receptor expression on CD4+ T cells. Additionally, when TLR7/8 is
triggered, an IFN-α anti-viral state is produced (22). Of the subset of cells that produce an
anti-viral state, pDCs seem most likely to be responsible, as they produce the highest
levels of anti-viral IFN-α (100-102). However, it has been shown that of the cell
population in lymphoid tissue, it is B cells that mediate the TLR7/8-dependant anti-HIV
effects, which implies a role for B cells in innate immunity. In contrast to acute infection,
TRL7/8 activation in latently infected cells results in release of HIV virions and the
activation of HIV replication in the cells of the myeloid-macrophage cell line (22).
2.5: Fr98 Retrovirus System
The group of lentiviruses that induce immunodeficiency such as HIV, SIV, FIV,
and Fr98, a polytropic murine retrovirus, all induce severe clinical CNS disease. (103108). Fr98 is a polytropic retrovirus and was created by combining a rapidly replicating
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retrovirus (FB29) with the cloned envelope gene of an extremely neurovirulent virus
(FMCF98) (107). Fr98 primarily infects CNS microglia cells, macrophages, and
occasionally oligodendrocytes (108). In the brain, Fr98 produces astrogliosis,
microgliosis, and mild vacuolar and neuronal degeneration (1, 107). Fr98 produces the
same neurological disease and pathology as FMCF98, but CNS disease is seen 20-30
days post-infection instead of 6-8 months (108). Clinical disease consists of ataxia, hind
limb weakness, tremors, seizures, and death (107). A comparative study of Fr98 and the
non-neurovirulent chimeric polytropic retrovirus Fr54 demonstrated that the two viruses
were very similar in that they infect the same cell types, cause similar pathology, induce
no significant changes in apoptosis gene expression, and had no associated lymphocytic
infiltrates (2, 109). The lack of inflammatory infiltrates implies that the innate immune
response is mediating the pro-inflammatory cytokine and chemokine response. Fr98
differs, however, in that it produces a much higher viral load than Fr54 and activates
astrocytes and microglia/macrophages. In Fr98 pathogenesis there is also significant gene
up-regulation of pro-inflammatory cytokines and chemokines, which does not occur in
Fr54 retrovirus infections. Up-regulated pro-inflammatory genes in Fr98 infection
include: Tnfα, Tnfβ, Il-1α, Ccl2, Ccl3, Ccl4, Ccl5, Ccl7, Ccl12, Cxcl1, and Cxcl10 (1, 2).
The structural difference between Fr98 and Fr54 that results in these differences is in the
envelope protein. Currently, two neurovirulent determinants have been discovered on the
Fr98 genome which appear to be mechanistically different yet complementary to each
other (2, 109).
We studied the mechanism by which TLR7 contributes to neuroinflammation in
the neonatal brain using a mouse model of polytropic retrovirus infection. In this mouse
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model, infection of neonatal mice with the neurovirulant polytropic retrovirus, Fr98,
induces severe clinical neurologic disease characterized by ataxia, seizures, and/or death
by 2-3 weeks post-infection. The effects of retrovirus infection in the CNS include viral
encephalitis with associated microgliosis, mild vacuolar and neuronal degeneration,
astrogliosis, and minimal mononuclear cell infiltrates (1, 107). Fr98 primarily infects
CNS microglial cells, macrophages, endothelial cells, and occasionally oligodendrocytes,
suggesting an indirect mechanism of neuropathogenesis (107, 108). One mechanism by
which Fr98 induces neuropathogenesis may be the up-regulation of pro-inflammatory
cytokines and chemokines, which correlates with neuropathogenesis. In the current study,
TLR7 knockout mice were used to examine the role of TLR7 in virus-mediated host
neuroinflammatory responses and pathogenesis induced by Fr98 infection. We found that
TLR7 had a significant impact on cytokine and chemokine induction and astrocyte
activation during retrovirus infection.
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Chapter 3: Materials and Methods
3.1: Solutions
10X Tris buffered EDTA (TBE)
108 g Tris base (890 mM)
55 g boric acid (890 mM)
40 ml 0.5 M EDTA, pH 8.0
Mix completely and stored at RT.
1X Tris buffered EDTA (TBE)
100 ml 10X stock TBE
900 ml ddH2O
Mix completely and stored at RT.

3.2: Mouse Strain
TLR7-deficient C57BL/6 mice (89) were backcrossed with Inbred Rocky
Mountain White (IRW) mice for eight generations prior to use. The Tlr7 gene is located
on the X chromosome. To generate litters of 50% TLR7+ (+/- or +) and TLR7- (-/- or -)
male mice containing the Tlr7 allele were mated with Tlr7 heterozygous females. All
mice were maintained at the Louisiana State University School of Veterinary Medicine,
which is fully accredited by the Association for the Assessment and Accreditation of
Laboratory Animal Care. All animal experiments were conducted in accordance with the
regulations of the Louisiana State University Institutional Animal Care and Use
Committee and the guidelines set forth by the National Institutes of Health.
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3.3: Genotyping for Tlr7 Wild-type and Knockout Alleles
DNA was isolated from individual mouse tail biopsies using Sigma GenElute
Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich, St. Louis, MO). A dry heat
block was preheated to 55oC and all kit reagents were thoroughly mixed by shaking. The
Wash Solution was prepared by mixing 1 part Wash Solution Concentrate with 4 parts
EtOH. Proteinase K was dissolved in sterile ddH2O and mixed by pipetting to obtain a 20
mg/ml stock solution. One Miniprep binding column and three 2 ml collection tubes were
labeled for each sample. Tail biopsies were removed from -80oC storage, and each was
placed in a 1.5 ml microcentrifuge tube. To each tube, 180 μl of Lysis Solution T and 20
μl of Proteinase K solution were added to digest the tissue. The samples were then
vortexed to ensure that the tail biopsies were completely submerged. The samples were
incubated at 55oC on the dry heat block for 4-6 hours with hourly vortexing until
completely digested. After digestion the samples were vortexed and 20 μl of RNAse A
solution was added to each sample to remove residual RNA. The samples were allowed
to incubate in the RNAse A solution for 2 minutes at room temperature. 200 μl of Lysis
Solution C was then added to lyse the cells, and the samples were vortexed thoroughly
for 15 seconds. To each Miniprep Binding Column, 500 μl of Column Preparation
Solution was added and centrifuged at 12,000 x g for 1 minute to maximize the binding
of DNA to the membrane. The flow-through was discarded and 200 μl of 100% EtOH
was added to the lysate and vortexed for 5-10 seconds to prepare for binding. The entire
contents of the tube were transferred into the treated binding column using a wide-orifice
pipette tip (to reduce shearing the DNA) and centrifuged at > 6,500 x g for 1 minute. The
collection tube was discarded and the binding column was placed in a new 2 ml
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collection tube. 500 μl of the appropriately diluted Wash Solution was added to the
binding column and centrifuged at 6,500 x g for 1 minute. The Wash Solution was
necessary because the binding column must be free of ethanol before the DNA is eluted.
Once again, the collection tube was discarded and the binding column was placed in a
new 2 ml collection tube. Another 500 μl of Wash Solution was added to the binding
column and samples were centrifuged at > 16,000 x g for 3 minutes to dry the binding
column. The collection tube was discarded and the binding column was placed in a new
2 ml collection tube. Directly into the center of the binding column, 200 μl of the Elution
Solution (10 mM Tris-HCl, 0.5 mM EDTA) was added and left to incubate at room
temperature for 5 minutes to increase the elution efficiency. The samples were
centrifuged at 6,500 x g for 1 minute to elute the DNA. The binding column was
discarded and genomic DNA (gDNA) samples were stored at 4oC for short-term storage.
For analysis by PCR, gDNA samples were removed from storage and placed on
ice. A master mix was made using 8 μl of nuclease-free water, 8 μl Eppendorf®
MasterMix 2.5x (containing: Taq DNA Polymerase (0.0625 U/μl), 125 Mm KCl, 75 mM
Tris-HCl pH 8.3, 3.75 MgCl2, 0.25% Nonidet® -P40, 500 μM of each dNTP stabilizers),
1 μl TLR7 forward primer, 1 TLR7 reverse primer, and 1 μl TLR7 wildtype primer for
each sample run. The master mix was dispensed into tubes and the appropriate samples
were added and vortexed and quickly centrifuged. Detection of both wild-type and
knockout alleles were completed in the same PCR reaction using the Tlr7 forward
primer: TCC AGT GTC ATG CCT ACC TGT in combination with the Tlr7 wild-type
primer: GGC GGT CAG AGG ATA ACT TGT and the Tlr7 knockout primer: ATG CCT
GCT TGC CGA ATA TC. Products were amplified under the following conditions: 94oC
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for 3 min, followed by 25 cycles at 94oC for 30 s, 60oC for 30 s and 70oC for 30 s, and
72oC for 10 min. After the PCR reaction was completed, 5 μl Cresol red/40% Glycerol
loading dye was added to sample. Samples were run on a 1.5% agarose gel which was
made by adding 1.5 g agarose to 100 ml 1X TBE. The mixture was microwaved for 120
seconds at full power until the agarose had dissolved. The flask was removed, 3 μl EtBr
was added and the agarose was mixed by swirling the flask. The mixture was poured into
the gel caster and 26-well combs were inserted. The gel was allowed to cool. Once set,
the gel was placed in the mini-gel tank and covered in 1X TBE. The combs were
removed and 10 μl of the BioRad EzLoad HT Molecular Marker (Bio-Rad Laboratories,
Hercules, CA) was added to the first and last lanes and 10 μl of sample were loaded into
the appropriate lanes. The lid was placed on and the gel was run at 150 V for 30 minutes
or until the dye was half-way down the gel. The gel was viewed on a FluorChem 8800
(Alpha Innotech, San Leandro, CA). Wild-type alleles were detected by a 250 bp band,
and knockout alleles were detected by a 450 bp band. Expression of Tlr7 mRNA
correlated with the Tlr7+/-, + and -/-, - genotypes.
3.4: Virus Infection and Sample Collection
The construction of virus clone Fr98 has been previously described (107). Virus
stocks were prepared from the supernatant of Fr98 or mock-infected Mus dunni fibroblast
cell cultures. Envelope-specific monoclonal antibodies 514 and 720 were used in focus
forming assays to determine virus titers (110). Virus stocks were stored at -80oC until
use. Newborn IRW mice were infected intraperitoneally (i.p.) with 100 μl of cell culture
supernatant containing mock virus or 104 focus-forming units (FFU) of Fr98 virus within
24 hours of birth using a 27 ½ gauge needle and 1 ml syringe (Becton Dickinson,
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Franklin Lakes, NJ). Mice were observed daily for clinical signs of CNS disease, which
include ataxia and/or seizures (107). At the onset of clinical disease or the appropriate
time point, animals were euthanized under isoflurane anesthesia via exsanguination by
cardiac puncture. Brains, spleens, tails, and serum were collected from each animal and
flash frozen in liquid nitrogen and stored at -80oC. Prior to freezing, brains were divided
in half sagittally with one half immersion-fixed in 3.7% neutral buffered formalin (NBF)
for 48 hours and kept in 70% ethanol until histological processing and the other half flash
frozen in liquid nitrogen and stored at -80oC for RNA isolation or multiplex analysis.
3.5: Histological Analysis
Hemisected brain tissue samples were immersion fixed in 3.7% neutral-buffered
formalin for 48 h, embedded in paraffin and cut in 4-μm para-central saggital sections
that included cerebrum, cerebellum, and brainstem. Tissue sections were then adhered to
coated microscope slides and stained with hematoxylin and eosin (H&E) using an
automated histological stainer. Additional tissue samples were stained with antibodies to
virus envelope, CD3 (Dako, Carpinteria, CA), or active-caspase 3 (Promega, Madison,
WI) as described below. Slides were examined in a blind fashion for histopathological
evidence of neuroinflammation and neurodegeneration.
3.6: Immunohistochemistry Analysis
Sections were incubated twice in xylene for fifteen minutes to remove residual
paraffin and rehydrated with five minute incubations in 100%, 95%, 70% ethanol, and
twice in PBS. Antigen retrieval was performed using sodium citrate antigen retrieval
buffer in a decloaking chamber (Biocare Medical, Concord, CA) set at 120oC for 20
minutes and cooled to 90oC. Pressure consistently read between 12-15 psi. When slides
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reached 90oC, they were rinsed four times with ultra pure water by replacing half of the
volume of antigen retrieval solution with water. Slides were then washed twice with
0.5% coldwater fish skin gelatin (Sigma Aldrich, St. Louis, MO) /PBS (0.23% FSG/PBS)
for ten minutes on a rocker. Slides were incubated in a humidity chamber (Evergreen
Scientific, Los Angles, CA) in 175 μl normal donkey serum blocking solution for at least
30 minutes. Slides were incubated overnight at 4oC with primary antibody. TLR7
antigen was detected using a polyclonal rabbit anti-TLR7 antibody (Zymed, Carlsbad,
CA), with biotinylated goat anti-rabbit secondary antibody and streptavidin conjugated to
AlexaFluor 555 (Invitrogen, Carlsbad, CA). CD31 was detected using a goat polyclonal
antibody to mouse CD31 and a rabbit anti-goat antibody conjugated to AlexaFluor 488
(Invitrogen). gp70 was detected using a rabbit anti-goat IgG conjugated to AlexaFluor
555 (Invitrogen). Secondary antibodies were applied at a dilution of 6.67 μg/ml in 0.5%
FSG/PBS and incubated for at least 30 minutes at room temperature. All sections were
counterstained with DAPI. Slides were rinsed twice in 0.5% FSG/PBS. Slides were
mounted with ProLong Gold anti-fade reagent (Invitrogen) and allowed to set for at least
two hours at 4oC.

An irrelevant rabbit anti-mouse Ig antibody did not produce

detectable fluorescence. Images were psuedo-colored and overlayed using ImagePro
Plus software.
3.7: Mutiplex Assay for Chemokine Expression
Brain tissue samples were retrieved from -80oC storage, weighed, and
homogenized in 400 μl of Bio-Plex cell lysis solution (BioRad) containing Complete
Mini protease inhibitors (Roche Applied Science, Indianapolis, IN) and 2 mM
phenylmethylsulfonyl fluoride (Sigma Aldrich) was added. Samples were homogenized
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using Kontes Disposable Pellet Pestles and a cordless motor (Fisher Scientific, Hampton,
NH) and diluted to 400 μg/ml in lysis buffer. Samples were centrifuged at 4500 x g for 15
min at 4oC; cellular debris was removed and the supernatants were collected and held on
ice until use. Cytokine protein expression was analyzed using a BioRad 6-plex assay
(BioRad, Hercules, CA). A working wash buffer was prepared by warming the 20X
concentrate to room temperature and vortexing it to remove any precipitate. 15 ml of
wash buffer concentrate was mixed with 285 ml deionized water in a 500 ml media
bottle. The assay diluent was prepared by diluting it with an equal volume of lysis buffer.
To set up for vacuum aspiration, a plate lid was placed on the manifold (with metal grid)
and the house vacuum was turned on. Then the valve was opened to the manifold and the
vacuum was adjusted to less than 5” Hg. The valve to the manifold was closed and the
plate lid was removed. To perform vacuum aspiration, the valve was opened to the
manifold and the loaded plate was placed on the manifold. Once the aspiration was
complete (< 3 seconds), the valve to the manifold was closed and the plate was removed.
The bottom of the plate was blotted with a Kimwipe (Kimberly-Clark, Irving, TX) and
the plate was placed on an inverted lid to load. Within an hour of use, the standard was
prepared to a total volume of 1 ml. For the 6-plex standard, 1 ml of diluent was added to
the vial and left to sit at room temperature for 10 minutes. Six 300 μl diluent tubes were
prepared along with one 300 μl diluent blank. The standard vial was inverted to mix and
then serial three-fold dilutions were performed by transferring 150 μl starting with the
standard into 300 μl, then mixing, changing tips, and transferring. A plate map of samples
to be run was made, and the plate was pre-wet by adding 200 μl of wash buffer to each
well of the plate. The wash buffer was allowed to sit for 15-30 seconds and then vacuum
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aspirated and blotted with a Kimwipe. Immediately prior to use, the 6-plex beads were
vortexed for 30 seconds and then sonicated for 30 seconds. The beads were washed by
adding 25 μl beads per well and 200 μl wash buffer to each well of the plate. The
beads/wash buffer mixture was allowed to sit for 15-30 seconds and then was vacuum
aspirated. A wash was performed by the addition of 200 μl of wash buffer, allowing the
plate to sit for 15-30 seconds, followed by vacuum aspiration. The bottom of the plate
was wiped with a Kimwipe. The standard and sample reactions were then prepared by
adding 50 μl Incubation buffer to each well. 100 μl of standard and blank were added to
designated duplicate wells, and 50 μl of appropriate assay diluent was added to sample
wells. Then 50 μl of clarified sample was added to designated duplicate wells, resulting
in a 1:2 dilution of sample. The plate was covered to protect the beads from light for the
rest of the assay and allowed to incubate at room temperature on an orbital shaker at 500600 rpm for 2 hours. 10-15 minutes prior to the end of the incubation, the biotinylated
detector antibody (BioRad) was prepared by diluting 1 ml of the 10X concentrate with 9
ml biotinylated detector antibody diluent (BioRad) in a non-Corning 15 ml polypropylene
conical tube. After the 2 hour incubation was complete, the plate was vacuum aspirated
and the previously described wash was repeated twice. The bottom of the plate was
wiped with a Kimwipe. 100 μl of diluted biotinylated detector antibody was added to
each well and the plate was covered and allowed to incubate at room temperature on an
orbital shaker at 500-600 rpm for 1 hour. 10-15 minutes prior to the end of the
incubation, the Strepavidin-RPE (BioRad) was prepared by diluting 1 ml of the 10X
concentrate with 9 ml Strepavidin-RPE Diluent in a foil wrapped non-Corning 15 ml PP
conical tube. The beads were then washed twice as previously described above. To each
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well, 100 μl of Strepavidin-RPE was added and allowed to incubate at room temperature
on an orbital shaker at 500-600 rpm for 30 minutes. The beads were then washed and
vacuum aspirated three times as described above. 100-125 μl of wash buffer was added
to each well and the plate was covered. Immediately prior to reading, the plate was
placed on an orbital shaker at 500-600 rpm for 2-3 minutes. Cytokine protein expression
was then analyzed using a Bio-Plex system instrument (Bio-Rad). Samples were
calculated as pg/ml using a standard curve from in-plate standards and subsequently
converted to fg/mg of brain tissue.
Table 1: Cytokines and Chemokines of Interest
Cytokine/Chemokine
Abbreviation
IL-12p70

Cytokine/Chemokine Full
Name
Interleukin-12

MIP-1α

Chemokine ligand 3

MIP-1β

Chemokine ligand 4

MCP-1

Monocyte chemoattractant
protein 1
Chemokine ligand 5
Tumor necrosis alpha

RANTES
TNF-α

Cytokine/Chemokine
Function
Induces INFγ production by
T cells
Monocyte/lymphocyte
attractant
Monocyte/lymphocyte
attractant
Monocyte attractant
Lymphocyte attractant
Involved in apoptosis and
cell proliferation

3.8: Preparation of RNA for Real-Time PCR analysis
Tissues were removed from storage at -80oC and transferred to a TropiCooler set
at -10oC. Tissues were homogenized in 2 ml of Trizol reagent (Invitrogen), an effective
inhibitor of RNase activity, in a sterile dounce homogenizer, pestle size B. The
homogenate was divided into two 1.5 ml centrifuge tubes, and the homogenizer was
rinsed with 1 ml of Trizol between samples. To allow for complete dissociation of
nucleoprotein complexes, homogenates were left at room temperature for 5 minutes, and
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then 200 μl of chloroform was added to each tube. Tubes were then shaken for 15
seconds and then incubated for 2-3 minutes at room temperature. The samples were then
centrifuged at 12,000 x g for 15 minutes at 4oC in an Eppendorf table-top centrifuge to
create a phenol-chloroform phase (proteins), an interphase (DNA), and an RNA
containing upper aqueous phase. The aqueous phase was removed and transferred to a
new 1.5 ml centrifuge tube. RNA was precipitated using 600 μl isopropanol and the
samples were incubated for at least 10 minutes at room temperature. Samples were then
centrifuged at 12,000 x g for 10 minutes at 4oC. The RNA precipitate formed a gel-like
cloudy pellet at the bottom of the tube. The supernatant was poured off all samples, 1 ml
of 70 % ethanol was added and the samples were briefly vortexed to dislodge and wash
the RNA pellet. The samples were centrifuged at 7,500 x g for 5 minutes at 4oC and the
ethanol was poured off. The pellets were air dried for 5-10 minutes and 50 μl of RNAsefree water was added to solubilize the pellets. The samples were incubated at 55oC for 10
minutes on a dry heat block, briefly vortexed and then centrifuged, then placed in storage
at -80oC.
Following Trizol purification, all RNA samples were subsequently treated with
DNase (Ambion, Austin, TX) to remove any residual genomic DNA from the purified
RNA. Using the Ambion DNase I kit, a master mix was made by combining 10 μl
DNase buffer, 15 μl (30 units) of DNase I, and 70 μl RNase-free water for each sample.
For each RNA sample, 95 μl of the master mix was added to a clean 1.5 ml centrifuge
tube and 10 μl of the appropriate sample was added. The master mix and sample were
mixed by pipetting, and then briefly centrifuged and incubated at 37oC for 30 minutes,
allowing the DNase I enzyme to degrade any gDNA that could result in false positive
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signals in subsequent RT-PCR. Samples were then purified over Zymo RNA Cleanup
Columns (Zymo Research). To each sample, 400 μl of RNA-Binding buffer (Zymo
Research) was added, pipetted to mix, and was then transferred to a Zymo-spin column
and centrifuged for 30 seconds at full speed. The RNA, bound to the column by the
RNA-Binding buffer, was washed twice with 350 μl of Wash Buffer (Zymo Research)
and centrifuged for 30 seconds at full speed to remove Wash Buffer residues. RNA was
eluted by adding 50 μl of RNase-free water to the column and briefly centrifuging it at
>10,000 x g. The eluent was used immediately or stored at -80oC.
The RNA was reverse-transcribed to make cDNA for RT-PCR using an iScript
Reverse Transcription kit (Bio-Rad). First, a master mix was made using 10 μl nucleasefree double distilled water, 4 μl of 5x iScript Reaction Mix, and 1 μl iScript reverse
transcriptase (iScript RT) for each sample. For the non-reverse transcribed (no-RT)
controls, 1 μl of water was used in place of the iScript RT. In a 0.5 ml tube, 5 μl of the
appropriate sample and 15 μl of the master mix were mixed together. Additionally,
control samples of RNA were made and serially diluted 1:5, 1:25, and 1:125 to measure
the efficiency and sensitivity of the reverse transcription process. The samples were then
placed in an MJ Research PTC Thermal Cycler (MJ Research Inc., Quebec, Canada) and
run under the following conditions: 25oC for 5 minutes, 42oC for 30 minutes, 85oC for 5
minutes, and held at 20oC until removed. Following the reverse transcriptase reaction,
samples were briefly centrifuged and diluted four-fold in RNase-free water. cDNA was
stored at -20oC prior to use in real-time PCR reactions.
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3.9: Real-time PCR Analysis of Gene Expression
A master mix was made using 17.5 μl 2x iTaq SYBR Green Supermix with Rox
(Bio-Rad), 1.75 μl of forward and reverse primers (1.8 μM final concentration) and 9 μl
RNase-free H2O for a total volume of 30 μl per sample. In a 96 well plate kept on a
cooling block, 30 μl of master mix was dispensed into each well and 5 μl (10 ng) of
cDNA or water was added to the appropriate well. The plate was covered with
RNase/DNase-free film, vortexed to mix, and centrifuged at 1500 rpm for 5 minutes. The
film was removed and the samples were dispensed 10 μl per well in triplicate into a 384
well plate (Applied Biosystems, Foster City, CA) using a Matrix electronic repeating
pipette (Matrix Technologies, Hudson, NH). Once again, the plate was covered with
RNase/DNase-free film and centrifuged at 1500 rpm for 5 minutes. Plates were kept at
4oC until analysis on an ABI PRISM 7900 Sequence Detection System (Applied
Biosystems). Primers for real-time PCR analysis are shown in Table 2. All primers used
for real-time analysis were designed using Primer3 software (111). To confirm that all
primer pairs were specific for the gene of interest and that no homology to other genes
was present, primers were compared against the National Center for Biotechnology
Information (NCBI) website. Analysis of dissociation curves was used to confirm the
amplification of a single product for each primer pair per sample. Confirmation of a lack
of DNA contamination was achieved by running reactions without reverse transcriptase.
Untranscribed controls had at least a 1000-fold lower expression level than analyzed
samples or were negative for all genes after 40 cycles. Gene expression was quantified by
the cycle number at which each sample reached a fixed fluorescence threshold (CT). To
control for variations in RNA amounts among samples, data were calculated as the
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difference in CT values (log2) between Gapdh and the gene of interest for each sample
(ΔCT = CT Gapdh – CT gene of interest). Therefore, data are presented as a percentage of
Gapdh expression for each gene of interest.
3.10: Statistical Analysis
All statistical analyses were performed using Graph-Pad Prism software (San Diego, CA)
using the appropriate statistical test as stated in each figure legend. Indications of
statistical significance are: * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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Table 2. List of primers used for real-time PCR analysis.
Common gene Name
NCBI Gene
Forward primer
Symbol & ID#
Actin
Actb: 11461
CAGCTTCTTTGCAGCTCCTT
CD3 antigen epsilon
Cd3e: 12501
GAGCACCCTGCTACTCCTTG
Chemokine ligand 2 (MCP-1)
Ccl2: 20296
TCCCAATGAGTAGGCTGGAG
Chemokine ligand 3 (MIP-1α)
Ccl3: 20302
ACCATGACACTCTGCAACCA
Chemokine ligand 4 (MIP-1β)
Ccl4: 20303
AGTCCCAGCTCTGTGCAAAC
Chemokine ligand 5
Ccl5: 20304
GGTTTCTTGATTCTGACCCTGT
(RANTES)
A
Chemokine ligand 10 (IP10)
IP10: 15945
CAGTGAGAATGAGGGCCATAG
G
Friend murine leukemia virus
gag: 1491876
AAACCAATGTGGCCATGTCATT
Fb29 gag (gag)
F4/80
Emr1: 13733
TTACGATGGAATTCTCCTTGTA
TATCA
Glyceraldehyde-3-phosphate
Gapdh: 407972
TGCACCACCAACTGCTTAGC
dehydrogenase (Gapdh)
Glial fibrillary acidic protein
Gfap: 14580
CGTTTCTCCTTGTCTCGAATGA
(GFAP)
C
Integrin alpha X (Cd11c)
Cd11c: 16411
ATGTTGGAGGAAGCAAATGG
Interferon beta (Ifnb1)
Ifnb1: 15977
AGCACTGGGTGGAATGAGAC
Myeloid differentiation primary Myd88: 17874
CATGGTGGTGGTTGTTTCTG
response 88 (MyD88)
Toll-like receptor 3
Tlr3: 142980
AGCTTTGCTGGGAACTTTCA
Toll-like receptor 4
Tlr4: 21898
GGCAGCAGGTGGAATTGTAT
Toll-like receptor 7
Tlr7: 170743
GGCATTCCCACTAACACCAC
Toll-like receptor 8
Tlr8: 170744
TCGTCTTGACCATTTGTGGA
Toll-like receptor 9
Tlr9: 81897
ACTTCGTCCACCTGTCCAAC
Tumor necrosis factor alpha
Tnf: 21926
CCACCACGCTCTTCTGTCTAC
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Reverse Primer
CACGATGGAGGGGAATACAG
TGAGCAGCCTGATTCTTTCA
CCTCTCTCTTGAGCTTGGTGA
GATGAATTGGCGTGGAATCT
CCACGAGCAAGAGGAGAGAG
AGGACCGGAGTGGGAGTAG
CTCAACACGTGGGCAGGAT
AAATCTTCTAACCGCTCTAACT
TTCG
CACAGCAGGAAGGTGGCTATG
TGGATGCAGGGATGATGTTC
TCGCCCGTGTCTCCTTGA
TGGGGCTGACTTAGAGGAGA
TCCCACGTCAATCTTTCCTC
CTGTTGGACACCTGGAGACA
ATCGAGCTGGGTGAGATTTG
AGGATTCGAGGCTTTTCCAT
TTGGACCCCAGTAGAACAGG
AATGCTCCATTTGGGATTTG
TCATGTGGCAAGAGAAGTGC
GAGGGTCTGGGCCATAGAA

Chapter 4: Results
4.1 Effect of TLR7 Deficiency on Fr98-induced Neurologic Disease
To analyze the role of TLR7 in neuropathogenesis, TLR7+ and TLR7- littermates
were infected i.p. with Fr98 or mock culture supernatants within 24 hours of birth and
followed for the development of clinical disease. No significant difference in the
development of neurologic disease was observed in TLR7- mice versus TLR7+ mice
(Fig. 3). Additionally, there were no notable distinctions in the histopathology of Fr98infected TLR7+ and TLR7- mice as detected in hematoxylin and eosin (H&E) stained
sections or in tissue sections stained with antibodies to CD3, viral envelope protein or
active caspase 3 (data not shown). Thus, TLR7 did not appear to play a critical role in
the development of Fr98-mediated neurologic disease.

% ataxic or dead

100

TLR7 +/- or +
TLR7 -/- or -

75
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days post infection
Figure 3. Analysis of the effect of TLR7 deficiency on neurologic disease. Development
of neurologic disease in TLR7 positive (+/- or +) and TLR7 deficient (-/- or -) Fr98infected mice and age-matched control mice. At the time of clinical disease, mice were
genotyped for Tlr7 positive and knockout alleles. Data are presented as the percentage of
mice (14 TLR7- mice and 15 TLR7+ mice) with severe ataxia or death. Data was
analyzed using Kaplan-Meir survival curve and log-rank post-test.
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4.2 Effect of TLR7 on Viral Replication, TLR8, TLR9, and the MyD88 Signaling
Pathway in the Brain
To determine if TLR7 alters virus replication during infection, we analyzed brain
tissue from mock and Fr98-infected TLR7+ and TLR7- mice for expression of virus gag
RNA at 14 dpi, just prior to the development of clinical neurologic disease. No
significant difference was observed in viral gag RNA expression in the brains (Fig. 4A)
of Fr98-infected TLR7+ or TLR7- mice. Thus, TLR7-deficiency did not appear to
influence virus replication in the brain.
As expected, the presence of TLR7 was demonstrated by mRNA expression in
both the TLR7+ mock and Fr98 infected mice, and absent in both groups of TLR7- mice
(Fig. 4B). Since TLR7, TLR8, and TLR9 comprise a subfamily in which all are confined
to the membranes of endosomes and recognize similar molecular structures, the
oligonucleotide-based PAMPs, we analyzed Tlr8 and Tlr9 mRNA expression to
determine if any cooperative interactions among these receptors existed. A significant upregulation of Tlr8 mRNA by Fr98 infection was observed in both TLR7+ as well as
TLR7- mice (Fig. 4C). An approximate 3-fold increase was observed with Tlr9
expression in Fr98-infected TLR7+ mice compared to controls, although expression
levels varied substantially between mice, making the increase not statistically significant
(Fig. 4D). This increase was not observed in TLR7- mice (Fig. 4D). Additionally, we
examined the mRNA expression of Myd88, as it is the cytosolic adaptor protein
responsible for intracellular signaling initiation of TLR7, TLR8, and TLR9 (54, 55). No
significant difference was seen in Myd88 mRNA expression in the brain. Thus, multiple
members of the TLR9 family of receptors were up-regulated by Fr98 infection in
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wildtype mice. TLR7 deficiency may have an impact on TLR9 expression, but the
variability of TLR9 expression makes this difficult to determine.
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Figure 4. Analysis of the effect of TLR7 on viral replication, TLR8, TLR9, and the
MyD88 signaling pathway in the brain. Brain tissue from mock and Fr98-infected mice
was removed at 14 dpi, divided into two sagittal sections, snap frozen in liquid nitrogen
and processed for RNA. Real-time quantitative RT-PCR analysis was performed using
primers specific for (A) virus gag, (B) Tlr7 (C) Tlr8 (D) Tlr9 (E) Myd88. Data was
calculated as gene expression relative to Gapdh expression (% of Gapdh expression) for
each sample. Data are the mean +/- SEM for 5-6 mice per group. Data shown is from
one of two replicate experiments. Data analyses of TLR8 and TLR9 for both replicate
experiments was completed at the same time and were combined for graphing and
analysis. Statistical analysis was completed using a One-way ANOVA with Newman
Keuls post-test analysis. * = p<0.05, ** p<0.01.
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4.3 Effect of TLR7 Deficiency on Fr98-induced Cytokine and Chemokine
Production by Multiplex Analysis and Real-time Polymerase Chain Reaction
Fr98 infection of neonates induces substantial innate immune responses in the
brain including the production of proinflammatory cytokines as detected by both mRNA
and protein expression (1, 107, 108, 112, 113). To determine the role of TLR7 in the
innate immune response to Fr98 infection, brain tissue was analyzed for proinflammatory
cytokines and chemokines by multiplex bead array. Similar to previous reports, Fr98
infection of TLR7+ mice induced a significant up-regulation of CCL2 (MCP-1), CCL4
(MIP-β), and CCL5 (RANTES) protein levels (Fig. 5A-C) (1, 2). CCL3, TNF and Il12p70 protein levels were below sensitivity levels by multiplex bead array (data not
shown). In contrast to TLR7+ mice, only CCL5 protein was up-regulated significantly
by Fr98-infection in TLR7- mice (Fig. 5C). However, CCL5 expression was
significantly lower in TLR7- mice compared to TLR7+ mice (Fig. 5C). Thus, TLR7
appeared to play a non-redundant role in the induction of multiple pro-inflammatory
chemokines during retrovirus infection in the CNS.
Since some protein levels were too low for detection, we also analyzed gene
expression in the brain by real time polymerase chain reaction. Significant up-regulation
of Ccl3 (MIP-α), Cxcl10 (IP-10), Tnf (TNFα) and Ifnb1 mRNA levels were detected in
the brain of Fr98-infected wildtype mice at 14 dpi (Fig. 6A-C). TLR7 appeared to be
required for induction of Cxcl10 and Tnf mRNA, but was not necessary for Ccl3 or Ifnb1
mRNA up-regulation (Fig. 6A, 6D).
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Figure 5. Influence of TLR7 deficiency on Fr98-induced cytokine and chemokine (A-C)
protein levels in the brain. Brain tissue from mock and Fr98-infected mice was removed
at 14 dpi, snap frozen and processed for multiplex bead array. Analysis of (A) CCL2, (B)
CCL4 and (C) CCL5 protein levels in brain tissue. Results are the mean +/- standard
error of 5-6 mice per group. Statistical analysis was done by One-way ANOVA with
Newman Keuls post-test analysis. Statistical significance: * = p < 0.05, ** = p < 0.01.
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Figure 6. Influence of TLR7 deficiency on Fr98-induced cytokine and chemokine (A-D)
mRNA levels in the brain. Brain tissue from mock and Fr98-infected mice was removed
at 14 dpi, snap frozen and processed for real-time PCR analysis. Expression of (A) Ccl3
(B) Cxcl10 (C) Tnfa and (D) Ifnb1 mRNA. Data shown are the gene expression as a
percent of Gapdh mRNA expression for each sample. Results are the mean +/- SEM of 56 mice per group. Data shown is from one of two replicate experiments. Statistical
analysis was done by One-way ANOVA with Newman Keuls post-test analysis.
Statistical significance: * = p < 0.05, ** = p < 0.01.
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4.4 Effect of TLR7 on Peripheral Viral Replication and TLR7 Deficiency on Fr98induced Peripheral Cytokine Production
To investigate if TLR7 alters virus levels and cytokine production in the
periphery, we analyzed splenic tissue from mock and Fr98 infected TLR7+ and TLR7for expression of virus gag RNA at 14 dpi. No significant difference was observed in
viral gag RNA expression in the spleen (Fig. 7A) between Fr98-infected TLR7+ and
TLR7- mice. Thus, TLR7-deficiency did not appear to influence peripheral virus
replication.
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Figure 7. Expression of virus gag (A), Ifnβ1 (B), and Ccl3 (C) mRNA in the spleen of
mock and Fr98-infected TLR7 positive and TLR7 deficient mice at 14 dpi. Splenic tissue
from mock and Fr98-infected mice was removed at 14 dpi, snap frozen and processed for
real-time PCR analysis. Data are the mean +/- SEM of 5-6 mice per group. Data shown
is from one experiment. Statistical analysis was completed using One-way ANOVA
Newman Keuls post-test analysis. Statistical significance: * = p < 0.05.
In the spleen, mRNA for several cytokines including Ccl2 (MCP-1), Ccl4 (MIPβ), Ccl5 (RANTES), Ccl3 (MIP-α), Cxcl10 (IP-10), and Tnf (TNFα) were up-regulated in
Fr98-infected TLR7+ mice compared to mock-infected controls (data not shown). Of
these cytokines, only Ccl3 mRNA was not up-regulated by Fr98 in TLR7- mice (Fig.
7C). Fr98-induced Ifnb1 mRNA expression was lower in TLR7 deficient mice compared
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to wildtype controls, but not to a significant level (Fig. 7B). Thus, TLR7 only had a
limited role in peripheral immune responses to Fr98 infection.
4.5 Effect of TLR7 Deficiency on Fr98-induced Neuroinflammation
Activation of astrocytes, microglial cells, and macrophages is one of the primary
pathologic changes associated with Fr98 infections (107, 108). To examine if TLR7 was
involved in Fr98-induced activation of astrocytes and/or microglia/macrophages, we
analyzed TLR7+ and TLR7- mice at 14 dpi for mRNA expression of Gfap and F4/80 via
quantitative RT-PCR. GFAP and F4/80 are up-regulated on astrocytes and
microglia/macrophages, respectively, following activation (114-116). A significant
increase in Gfap and F4/80 mRNA expression was observed in Fr98-infected TLR7+
mice when compared to mock infected mice (Fig. 8A-B). However, Gfap and F4/80
were not up-regulated in TLR7- mice (Fig. 8A-B). The pattern of GFAP staining
observed by immunohistochemistry was inconclusive (data not shown).
To examine if TLR7 was involved in Fr98-induced up-regulation of other cellular
molecules, we also analyzed TLR7+ and TLR7- mice at 14 dpi for mRNA expression of
Cd3ε, Cd11c and Siglec-H via quantitative RT-PCR. Cd3ε is expressed by T cells,
Cd11c is expressed by a number of cell types including dendritic cells, and Siglec-H is
expressed by plasmacytoid dendritic cells. A significant increase in Cd3ε and Cd11c
mRNA expression was observed in Fr98-infected TLR7+ mice as compared to mock
infected mice (Fig. 8C-D). Additionally, Cd3ε and Cd11c mRNA was not up-regulated in
TLR7- mice. No increase in mRNA expression was observed for Siglec-H in Fr98infected TLR7+ or TLR7- mice (data not shown). Thus, Cdllc mRNA expression may be
due to microglial cells which up-regulate this molecule on activation, rather than
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recruitment of plasmacytoid dendritic cells which could migrate to the CNS in response
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Figure 8. Expression of Gfap (A), F480 (B) Cd3ε (C), and Cd11c (D) mRNA in the brain
of mock and Fr98-infected TLR7 positive and TLR7 deficient mice at 14 dpi. Tissue was
processed as described in Fig. 4. Real-time quantitative RT-PCR analysis was performed
using primers specific for Gfap, F480, Cd3ε, Cd11c, and Gapdh. Data are shown as the
gene expression as a percent of Gapdh mRNA expression for each sample. Results are
the mean +/- SEM of 5-6 mice per group. Data shown is from one of two replicate
experiments. Statistical analysis was done by One-way ANOVA with Newman Keuls
post-test analysis. Statistical significance: * = p < 0.05, ** = p < 0.01

4.6 Effect of TLR7 on Viral Replication and the Effect of TLR7 Deficiency on Fr98induced Neuroinflammation in Clinically Ill Animals
While we found that virus replication prior to clinical disease was not TLR7
dependent, we wanted to determine if TLR7 alters virus replication during active clinical
disease. To determine this, we analyzed brain tissue from mock and Fr98 infected
TLR7+ and TLR7- mice for expression of virus gag RNA when mice began to exhibit
clinical signs (ataxia, seizures). No significant difference was observed in viral gag RNA
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expression in the brain (Fig. 9A) of Fr98-infected TLR7+ and TLR7- mice. Thus, TLR7
deficiency did not appear to influence virus replication in the brain of preclinical or
clinically ill animals.
Since GFAP and F4/80 up-regulation was decreased in TLR7- mice in pre-clinical
animals, we analyzed Gfap and F4/80 mRNA expression in TLR7+ and TLR7- mice to
determine if this remained true in clinically ill animals. Surprisingly, a significant
increase in Gfap mRNA expression was observed in both Fr98-infected TLR7+ and
TLR7- mice as compared to mock infected mice (Fig. 9B). No up-regulation of F4/80
was observed at the time of clinical disease in either Fr98-infected TLR7+ or TLR7- mice
(Fig. 9C). Thus, TLR7 appears to play a role in stimulating astrocytes early in infection
(prior to day 14), but other mechanisms appear to compensate for the lack of TLR7 at
later stages of disease.
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Figure 9. Expression of virus gag (A), Gfap (B), and F4/80 (C) mRNA in the brain of
Fr98-infected TLR7 positive and TLR7 deficient mice and age-matched controls at the
time of apparent clinical disease (tremors, ataxia, seizures). Tissue was processed as
described in Fig. 4. Data are the mean +/- SEM of 7-8 mice per clinical disease group
and 3 mice per age-matched control group. Data shown is from one experiment.
Statistical analysis was completed using One-way ANOVA with Newman Keuls post-test
analysis. Statistical significance: * = p < 0.05.
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4.7 Effect of TLR7 Deficiency on Fr98-induced Cytokine and Chemokine
Production in Clinically Ill Animals
As Gfap mRNA was up-regulated in clinically ill TLR7- mice, we were interested
in whether other inflammatory markers were also up-regulated during the clinical stage of
disease. Tnf mRNA expression was significantly up-regulated by Fr98-infection in
TLR7+ mice, but was not up-regulated by Fr98-infection in TLR7- mice (Fig. 10F).
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Figure 10. Influence of TLR7 deficiency on Fr98-induced cytokine and chemokine
mRNA levels in the brain. Expression of Ccl2 (A), Ccl3 (B), Ccl5 (C), Cxcl10 (D), Ifnb1
(E), and Tnfa (F) mRNA in the brain of Fr98-infected TLR7 positive and TLR7 deficient
mice and age-matched controls at the time of apparent clinical disease (tremors, ataxia,
seizures). Tissue was processed as described in Fig. 4. Data are the mean +/- SEM of 78 mice per diseased group and 3 mice per age-matched control group. Data shown is
from one experiment. Statistical analysis was completed using One-way ANOVA with
Newman Keuls post-test analysis. Statistical significance: * = p < 0.05.
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For the other genes of interest, mRNA expression fluctuated too much to establish
significance; however, there was an observable trend of a more substantial increase of
cytokine and chemokine mRNA expression in the brain of clinically ill Fr98-infected
TLR7+ animals compared to Fr98-infected TLR7- mice (Fig. 10A-D). TLR7 appeared to
contribute to the induction of most cytokines and chemokines but had no effect on Ifnb1
mRNA expression (Fig. 10E). Thus, TLR7 may play a role in modulating the innate
immune response in both early and late stages of virus infection, with the exception of
Ifnb1.
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Chapter 5: Discussion
In the current study, TLR7 deficiency did not alter retroviral pathogenesis, but did
alter neuroinflammation, including astrocyte activation and chemokine production.
Thus, TLR7 appears to play an important role in the early glial response to retrovirus
infection, and inhibition of the pathway may reduce neuroinflammation. To date, this is
the first demonstration of the necessity of TLR7 for innate immune responses to
retrovirus infection in vivo. Additionally, these results indicate that the innate immune
response to retrovirus in the CNS may not be an essential step in the pathogenesis of the
disease.
TLR7 stimulation has been shown to both suppress and enhance HIV virus
replication in PBMC (22). In this study, TLR7 deficiency did not alter virus replication
in the brain or in the spleen of pre- or post-clinically diseased mice as measured by virus
gag RNA expression (Fig. 4A, 7A, 9A). This lack of an effect may be due to the
immaturity of the immune system in neonates. B cells play an important role in TLR7
mediation of HIV viral replication, and these responses are not fully developed in the
neonate. Additionally, spread of Fr98 may be restricted in the absence of an anti-viral
response. Unlike ecotropic retroviruses which infect microglia/macrophages throughout
the brain, polytropic retrovirus infection has a limited spread to microglia/macrophages
around blood vessels in the thalamus, hippocampus, corpus collosum, and cerebellum
(107). Thus, even in the absence of an anti-viral response, the spread of polytropic
viruses may be limited.
The lack of virus spread in TLR7 deficient animals may also be due to the
production of interferon beta. Ifnb1 mRNA was up-regulated in response to retrovirus
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infection in both TLR7 sufficient and deficient mice in the brain and the spleen of
animals prior to onset of clinical signs as well as in the brains of mice that exhibited
clinical signs of disease (Fig. 6D, 7B, 10E). Type 1 interferons, such as IFNβ, are
known to suppress the spread of the virus to uninfected cells (18, 19, 78, 79, 117). As
IFNβ up-regulation is a common downstream effect of TLR stimulation (69), it is
probable that stimulation of other TLR molecules are responsible for the Ifnb1 upregulation observed in the TLR7 deficient mice (Fig. 6D, 7B, 10E). For example, TLR4
has been shown to be activated by retroviral glycoproteins and can induce the expression
of Ifnb1 mRNA (118-122). Thus, TLR4 stimulation by Fr98 envelope proteins may be
sufficient for the induction of Ifnb1 mRNA in the absence of TLR7.
Despite the lack of effect on virus replication and clinical disease in this model,
TLR7-deficiency had a significant impact on neuroinflammatory responses. Many, but
not all, chemokines were reduced and cellular responses were also limited in both the
brain and in the periphery (Fig. 5A-C, Fig. 6A-D, Fig. 7B-C). Similar suppression of the
innate immune response was observed with TLR2 deficient mice following HSV-1
infection (14). Mice deficient in TLR3 had reduced infiltration of virus and immune cells
to the brain following West Nile virus infection (123). Thus, specific TLRs may play a
critical non-overlapping role in the initiation of immune responses to certain viruses. This
effect may be more profound in the developing brain, where limited immune cell
interaction reduces the possible mechanisms available for stimulation of immune
responses.
Another factor potentially influencing the neuroinflammatory responses observed
in the study is the cooperative interactions of the TLR7, TLR8, and TLR9 (TLR7/8/9)
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subfamily. Selective expression of murine TLR7, TLR8, and TLR9 in HEK293 cells has
demonstrated that co-expression of TLR8 or TLR9 inhibited TLR7 activation and
cytokine production (124). It is possible that selective activation and suppression within
the TLR7/8/9 subfamily provides a more tailored immune response to a specific
pathogen. In this study, both Tlr8 and Tlr9 mRNA appear to be up-regulated in TLR7+
Fr98-infected mice, with a statistical increase in Tlr8 mRNA expression (Fig. 4C-D).
However, only Tlr8 mRNA appeared to be up-regulated in TLR7 deficient Fr98-infected
mice. The observed up-regulation of Tlr8 mRNA in TLR7- mice may indicate that Tlr8
mRNA expression is not dependant on TLR7. The apparent lack of up-regulation of Tlr9
mRNA expression in TLR7- mice suggests that Tlr9 up-regulation may be dependent on
TLR7 stimulation: TLR7 agonist stimulation did induce Tlr9 mRNA up-regulation in an
astrocyte cell line (data not shown), suggesting a possible self-regulatory mechanism for
TLR7-induced responses.
Murine TLR8 was previously thought to be dysfunctional, based on the lack of
response of murine TLR7 deficient cells to viral ssRNA stimulation and TLR7/8 agonist
stimulation (125, 126). However, murine TLR8 is expressed on the embryonic and
neonatal brain and has been shown to play a role in regulating axonogenesis in the
developing nervous system and to inhibit neurite outgrowth and induce neuronal
apoptosis, in vitro (127). Possibly, TLR8 stimulation on neurons contributes to Fr98induced pathogenesis even in the absence of other inflammatory stimuli.
Differences and similarities in stimulation and signaling within the TLR7/8/9
subfamily may also influence inflammatory responses. As previously mentioned, ssRNA
genomes such as vesicular stomatitis virus, influenza A virus, and synthetic RNA
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oligonucleotide from HIV have all been found to activate TLR7 (18, 21) while TLR9
recognizes dsDNA genomes such as herpes simplex virus and murine cytomegalovirus
(64, 65, 79, 79). Additionally, it has been shown that during HIV infection, HIV-1 RNA,
not DNA retrotranscripts, appears to be essential for activating pDCs. However,
retroviruses, including HIV-1, may signal through both TLR7 and TLR9 (128). Possibly,
TLR9 is being stimulated by Fr98 viral CpG DNA fragments that have been released into
the cellular environment by infected apoptotic cells. Therefore, the neuroinflammatory
response observed in Fr98-infected mice may be due to multiple TLR stimulation, not
solely TLR7.
Due to their location, both TLR7 and TLR9 require endosomal acidification for
stimulation. It has recently been shown that for plasmacytoid dendritic cell activation and
subsequent IFNα production, TLR7 viral recognition and stimulation in pDCs requires
transport of viral replication intermediates into the lysosome by autophagy (129).
Because murine leukemia viruses may release their RNA into the cytosol (130),
stimulation of TLR7 may be through autophagy of infected cells or by uptake of
cellular/viral debris.
The requirement for TLR7 in Fr98-mediated up-regulation of multiple cytokines
and chemokines is interesting, as many of these cytokine and chemokine-producing cells
are not productively infected with virus. For example, Ccl2 and Cxcl10 mRNA is
produced by astrocytes (112), while Ccl3 and Ccl5 mRNA is produced by uninfected cell
types (131) (data not shown). The lack of cytokine and chemokine production correlated
with the lack of activation marker expression by astrocytes. As astrocytes are not
productively infected by Fr98, it is unclear how TLR7 influences their response to virus
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infection. Possibly, these cells are not directly activated through TLR7 signaling, but are
responding to a secreted cytokine or other signaling molecule produced by an infected
cell. This response may be inhibited in the absence of TLR7. Alternatively, astrocytes
and other uninfected cell types may take up viral particles including viral ssRNA by
phagocytosis or pinocytosis, leading to the activation of these cells through TLR7.
TLR7, TLR8, and TLR9 are expressed on lymphoid cellular subsets: B cells and
monocytes express TLR7 and 8, while pDC express TLR7 and TLR9, and CD11c
immature DC only express TLR8 (96, 132-134). A significant lack of mRNA expression
of Cd3ε and Cd11c in Fr98-infected TLR7 deficient versus Fr98-infected TLR7+ mice
was also observed in this study, indicating that activation of T cells and
dendritic/moncyte/macrophage cells is TLR7 dependent. No mRNA up-regulation was
observed in the expression of Siglec-H, a marker for pDCs, in Fr98-infected wildtype or
TLR7 deficient mice (data not shown), indicating that the cell types affected by TLR7
deficiency were mDC, monocytes or macrophages.
While TLR7 deficient mice sacrificed before clinical disease development
displayed significantly reduced expression by astrocytes and microglia/macrophages
compared to wildtype animals, mice which exhibited clinical signs of disease showed no
difference in Gfap mRNA up-regulation between Fr98-infected TLR7+ and TLR- mice.
Thus, TLR7 activation may stimulate astrocytes prior to the development of clinical
signs, but other mechanisms appear to compensate for the lack of TLR7 during later
stages of infection.
While not statistically significant (with the exception of TNF), mice which
developed clinical signs of disease displayed similar innate immune responses to those

43

sacrificed prior to the development of clinical disease at day 14 and the peak time
increase in cytokine and chemokine expression (1) (Fig. 10A-F). The variability of
cytokine and chemokine gene expression in Fr98-infected TLR7+ clinically ill mice was
surprising as we have previously shown that cytokine and chemokine expression is
significantly and repeatedly up-regulated following Fr98-infection in wildtype IRW mice.
The variability in gene expression in this experiment could be due to multiple reasons
including the variation in the age of the mice when they developed clinical signs (13-37
dpi) and the potential influence of heterozygosity (all females +/-, all males +) of the
genotype. Additionally, these studies were completed on mice that had only been
backcrossed for eight generations, not the full ten generations required for the residual
amount of unlinked donor genome in the strain to fall below 0.01 %. While each of the
effects may be minor, the combination may be sufficient to account for the variability
observed in the cytokine and chemokine results in the wildtype mice. That withstanding,
there was still a substantial up-regulation of cytokines and chemokines in wildtype mice
following Fr98-infection, but not in knockout mice.
The lack of a strong innate immune response to Fr98 infection in TLR7 deficient
mice is also interesting in light of potential mechanisms of neuropathogenesis. The
development of clinical disease by the TLR7 deficient mice indicates that the induction
of several components of the innate immune response is not essential for
neuropathogenesis. We have previously shown that TNFa and CCL2, two of the
molecules not induced in the TLR7 deficient mice, contribute to but are not necessary for
Fr98-mediated neurologic disease (2, 112). Possibly, the absence of both TNFa and
CCL2 negates the pathogenic and protective properties of both molecules. Although we
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did not observe any notable change in histopathology between Fr98-infected TLR7+ and
TLR7- mice, it is possible that other molecules were up-regulated in the TLR7 deficient
mice and that they contributed to disease pathogenesis, effectively compensating for the
lack of TLR7. It is also probable that the innate immune response may play a more
important role in slower developing neurologic disease compared to the rapid onset of
pathologic changes following Fr98 infection.
In the current study, TLR7 deficiency did not alter virus replication, clinical
disease, or influence the production of IFNβ1 in the brain. However, TLR7 deficiency did
alter neuroinflammation, including astrocyte activation and chemokine production.
Therefore, TLR7 appears to play an important role in the early glial response to retrovirus
infection, and inhibition of the pathway may reduce neuroinflammation. To further
define the role of TLR7 in neuropathogenesis, the neuroinflammatory and
neuropathogenic properties of the TLR7/8/9 family should be evaluated, as well as how
the interactions between TLR7, TLR8, and TLR9 elicit those responses. Additionally,
since it has been shown in this study that TLR7 has a non-redundant role in the induction
of neuroinflammatory responses in the CNS, it would be interesting to determine if the
roles of TLR7 and TLR9 are pathogenic or protective during retrovirus infection in the
neonatal brain. It would also be invaluable to determine how different TLR7, TLR8, and
TLR9 agonists affect the innate and adaptive immune responses to retrovirus infection in
the brain.
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